The terms, per the grant. On April 22, 2025, The Broad Institute was issued US12281303B2, covering methods and compositions for prime editing nucleotide sequences. The CPC tags — C12N 9/22 (nucleases), C12N 9/1276 (reverse transcriptase), C12N 15/11 and the C12N 2310 guide series — describe the prime-editing machinery that writes new sequence without a double-strand break.
Why a deals desk chases foundational editing IP: prime editing promises precise edits with fewer off-target and double-strand-break risks than first-generation CRISPR. Foundational method IP on a next-generation platform is the asset every commercial program in the space must license or design around — which is exactly what anchors platform deals.
The structure point: a foundational prime-editing license is a platform asset whose royalty base spans every program built on the technology. For a model, that is the broadest, most compounding value in the editing field — distinct from the narrower target-specific grants downstream.
What the grant does not promise: a clinical result, an approval, or that prime editing displaces existing modalities. It is an exclusivity claim on a foundational method, within a field where the foundational editing estates are valuable and contested.
The takeaway: when a next-generation editing deal crosses the desk, the foundational method grants are the load-bearing platform assets. The Broad's April 2025 prime-editing grant is a dated, concrete example of the IP that next-platform deals are written around.